Company: OPGN
Filing Date: 2025-10-01
Form Type: 10-Q
Source: 0001829126-25-007819
Chunk: 54

Company: OPGEN INC
Filing Date: 2025-10-01
Form: 10-Q
Item: Part I, Item 8
Chunk 54
---
 2025

    March 31, 2024

    (As Restated)

    (As Restated)

    Net (loss) income 
     
    $
    (408,133
    )
     
    $
    287,967

    $
    (408,133
    )
     
    $
    287,967

    Net income allocated to preferred stock

    -

    (84,462
    )

    -

    (84,462
    )
  
    Net (loss) income available to common stockholders
     
    $
    (408,133
    )
     
    $
    203,505

    $
    (408,133
    )
     
    $
    203,505

    Basic weighted average shares outstanding

    10,071,079

    1,284,305

    10,071,079

    1,284,305

    Dilutive effect of stock purchase warrants

    -

    47,273

    Dilutive weighted average shares outstanding

    10,071,079

    1,331,578

    (Loss) earnings per share
     
    $
    (0.04
    )
     
    $
    0.16

    $
    (0.04
    )
     
    $
    0.15

None of the potential dilutive securities had a dilutive impact during the three months ended March 31, 2025 due to the Company’s net loss.

The number of anti-dilutive shares for the three months ended March 31, 2025 and 2024 consisting of common shares underlying (i) common stock options, (ii) restricted stock units, and (iii) stock purchase warrants which have been excluded from the computation of diluted income per share, was 1.3 million and 1.1 million shares, respectively.

    13

Recently issued accounting standards

In July 2025, the FASB issued ASU No. 2025-05: Financial Instruments-Credit Losses which amends topic 326. Specifically, the ASU provides a practical expedient whereby an entity can assume that current conditions as of the balance sheet date will not change for the remaining life of the asset (e.g., the account receivable). This guidance is effective for the Company’s fiscal year ending December 31, 2026 and can be adopted early. The Company is in